Otsuka files twice FDA-rejected kidney drug tolvaptan in EU
This article was originally published in Scrip
Executive Summary
Feeling more confident with a Japanese approval for cirrhosis under its belt, Otsuka has filed for market approval of kidney drug tolvaptan in Europe.